(Q39276079)

10 September 2017

title

Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients (English)

1 reference

10 September 2017

0 references

Zhengbo Song

1

1 reference

10 September 2017

Yongfeng Yu

series ordinal

2

1 reference

10 September 2017

Zhiwei Chen

series ordinal

3

1 reference

10 September 2017

Shun Lu

series ordinal

4

1 reference

10 September 2017

publication date

30 November 2010

1 reference

10 September 2017

1 reference

10 September 2017

volume

28 Suppl 1

1 reference

10 September 2017

page(s)

S605-12

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-010-9753-3

10 September 2017

exact match

0 references

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9753-3

Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9753-3

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9753-3

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9753-3

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9753-3

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9753-3

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9753-3

Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9753-3

Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9753-3

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9753-3

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9753-3

A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9753-3

Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer

21 January 2018

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

12 December 2020

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

12 December 2020

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

12 December 2020

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer

1 reference

12 December 2020

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

1 reference

12 December 2020

Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy

1 reference

12 December 2020

A time trend of profile and surgical results in 1123 patients with non-small cell lung cancer

1 reference

12 December 2020

10.1007/S12032-010-9753-3

Identifiers

DOI

1 reference

10 September 2017

1 reference